Fig. 6. Comp 5 has a therapeutic potential on GBM in vivo.

a Comp 5 obviously decreased U87MG and T98G xenograft tumor volume. Dosage of administration, 25 mg/kg, 50 mg/kg, 100 mg/kg. b Representative tumors and the tumor weight change from mice after vehicle and Comp 5 treatment. ***P < 0.001, compared with control group. c Body weights of mice during Comp 5 treatment. d Organ indexes (kidney, liver, and spleen) of mice were assessed at the end of treatment. *P < 0.05, compared with control group. e Immunohistochemical staining of Ki-67. Tumor tissues were excised from the control and median dose group treated U87MG xenograft mice. Scale bar: 200 μm (left panel), 50 μm (right panel) f, g. Quantitative analysis of Ki-67 positive ratio. ***P < 0.001, compared with control group